ACIU

$3.32

Post-MarketAs of Mar 17, 8:00 PM UTC

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding.

Historical Price

Price (Line)
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$3.32
Potential Upside
5%
Whystock Fair Value$3.49
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryBiotechnology

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The compa...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$333.99M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-89.65%
Quick Ratio
Tight liquidity. Monitor cash flow carefully against debt.
0.98

Recent News

Associated Press Finance
Mar 13, 2026

AC Immune: Q4 Earnings Snapshot

LAUSANNE, Switzerland (AP) — AC Immune SA (ACIU) on Friday reported a loss of $18 million in its fourth quarter. The Lausanne, Switzerland-based company said it had a loss of 18 cents per share. The biopharmaceutical company posted revenue of $423,000 in the period.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
BioPharma Dive
Feb 20, 2026

Madrigal sees a stock sell-off; ex-Novartis exec heads to Daiichi

Madrigal shares fell 11% despite again topping consensus sales numbers. Elsewhere, Daiichi Sankyo named a new research chief and J&J halted recruitment in an Alzheimer’s trial.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
MT Newswires
Feb 18, 2026

Sector Update: Health Care Stocks Decline Late Afternoon

Health care stocks were lower late Wednesday afternoon, with the NYSE Health Care Index decreasing 0

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Simply Wall St.
Jan 13, 2026

Top Penny Stocks To Watch In January 2026

As the U.S. stock market experiences a pullback with investors assessing CPI inflation data and major bank earnings, attention turns to alternative investment opportunities like penny stocks. Often considered an outdated term, penny stocks still hold relevance as they represent smaller or newer companies that can offer growth potential at lower price points. When these companies are backed by strong financial fundamentals, they present intriguing options for investors seeking hidden value in...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Simply Wall St.
Jan 8, 2026

Retail investors are AC Immune SA's (NASDAQ:ACIU) biggest owners and were rewarded after market cap rose by US$53m last week

Key Insights AC Immune's significant retail investors ownership suggests that the key decisions are influenced by...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.